The Role of IL-17 in the Human Immune System and Its Blockage as a Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
- 1 May 2018
- journal article
- research article
- Vol. 17 (5), 539-542
Abstract
Interleukin 17 (11,17) functions as a bridge between the innate and adaptive immunity. In addition to being a crucial defense mechanism against extracellular pathogens, it plays a significant role in inflammation, therefore considered a decisive factor in inflammatory conditions; hence the importance of its understanding for the treatment of autoimmune diseases. Animal models have demonstrated that blockage of the IL-17 receptor (IL-17R) may prevent these pathologies. For instance, there is evidence that IL-17R-deficient mice may be protected against the development of collagen-induced arthritis (CIA) and experimental autoimmune encephalitis (EAE). Furthermore; inflammatory disorders such as rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PSA), and ankylosing spondylitis (AS) have been associated with 11,17, and therapeutically targeting this inflammatory pathway could improve patients' outcomes. The discovery and subsequent studies of this interleukin have aided in the understanding of the immune system, and its potential therapeutic blockage provokes optimism for the treatment of these distressing conditions.Keywords
This publication has 35 references indexed in Scilit:
- Immunity to infection in IL‐17‐deficient mice and humansEuropean Journal of Immunology, 2012
- IL-17 signaling in host defense and inflammatory diseasesCellular & Molecular Immunology, 2010
- Structure and signalling in the IL-17 receptor familyNature Reviews Immunology, 2009
- IL-17 and Th17 CellsAnnual Review of Immunology, 2009
- Psoriatic arthritis: from pathogenesis to therapyArthritis Research & Therapy, 2009
- The Biological Functions of T Helper 17 Cell Effector Cytokines in InflammationImmunity, 2008
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- The IL-23/IL-17 axis in inflammationJCI Insight, 2006
- Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineagesNature Immunology, 2005
- IL-23 drives a pathogenic T cell population that induces autoimmune inflammationThe Journal of Experimental Medicine, 2005